Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Talking Therapeutics

10/07/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, we explore whether the novel medication finerenone, which has a demonstrated benefit in patients with kidney disease, can also improve outcomes in patients with HFpEF.

In this installment of Talking...

10/07/2024

Pharmacy Learning Network

Talking Therapeutics

Are all SGLT2 Inhibitors Created Equal?

07/19/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, Dr Jennings explores a new study that evaluates dapagliflozin against empagliflozin in patients with heart failure.

In this installment of Talking...

07/19/2024

Pharmacy Learning Network